Literature DB >> 20656359

Patient information leaflets for antidepressants: are patients getting the information they need?

Camilla Haw1, Jean Stubbs.   

Abstract

BACKGROUND: According to European law a comprehensive patient information leaflet (PIL) has to accompany all medicines. In this study we examined the uniformity, adequacy and balance of information contained in UK antidepressant PILs.
METHODS: We studied antidepressant PILs available in the Electronic Medicines Compendium and subjected each to a content analysis. Words were assessed as being positive, negative or neutral.
RESULTS: Forty-two PILs concerning 21 different antidepressants and 23 pharmaceutical companies were studied. PILs presented information about side effects in a strikingly heterogeneous way, making it difficult for patients to find the required information. Half the PILs provided no information about how the antidepressant is thought to work. Over 90% stated the antidepressant would take 2-4 weeks to work, although a few PILs indicated earlier onset of improvement. Not all PILs warned about discontinuation syndrome and advice about alcohol was generally that it was prohibited. Almost half of PILs made no mention of St John's wort and its potential for interaction with the antidepressant. Two-thirds of PILs provided no information about the likely duration of treatment. PILs contained far more words judged to be negative rather than positive or neutral. LIMITATIONS: Data were extracted by a single researcher, although inter-rater agreement was high.
CONCLUSIONS: Further guidance and tightening of the approval process for PILs are needed to ensure they are more standardised in content and contain more information that is wanted by and is useful to patients.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20656359     DOI: 10.1016/j.jad.2010.06.034

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  7 in total

1.  Changes in Side Effect Risk Communication in Patient Information Leaflets over the Past Decade: Results of a Survey.

Authors:  Katherine Harris; Rebecca Dickinson; David K Raynor; Jan MacDonald; Peter Knapp
Journal:  Drug Saf       Date:  2015-08       Impact factor: 5.606

2.  Cessation of fluoxetine treatment increases alcohol seeking during relapse and dysregulates endocannabinoid and glutamatergic signaling in the central amygdala.

Authors:  Juan Suárez; Sophia Khom; Francisco Alén; Luis A Natividad; Florence P Varodayan; Reesha R Patel; Dean Kirson; Rocío Arco; Antonio Ballesta; Michal Bajo; Leticia Rubio; Rémi Martin-Fardon; Fernando Rodríguez de Fonseca; Marisa Roberto
Journal:  Addict Biol       Date:  2019-07-24       Impact factor: 4.280

Review 3.  A review of the management of antidepressant discontinuation symptoms.

Authors:  Emma Wilson; Malcolm Lader
Journal:  Ther Adv Psychopharmacol       Date:  2015-12

4.  Comparative analysis of package inserts of local and imported antihypertensive medications in Palestine.

Authors:  Sandra A Qatmosh; Amer A Koni; Baraa G Qeeno; Dina A Arandy; Maysa W Abu-Hashia; Bahaa M Al-Hroub; Sa'ed H Zyoud
Journal:  BMC Public Health       Date:  2017-09-25       Impact factor: 3.295

5.  Development and evaluation of user-tested Thai patient information leaflets for non-steroidal anti-inflammatory drugs: Effect on patients' knowledge.

Authors:  Narumol Jarernsiripornkul; Pacharaporn Phueanpinit; Juraporn Pongwecharak; Janet Krska
Journal:  PLoS One       Date:  2019-01-09       Impact factor: 3.240

6.  Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association.

Authors:  Andreas Vilhelmsson; Tommy Svensson; Anna Meeuwisse; Anders Carlsten
Journal:  BMC Pharmacol Toxicol       Date:  2012-12-23       Impact factor: 2.483

7.  Evaluation of medication package inserts in Saudi Arabia.

Authors:  Sinaa A Al-Aqeel
Journal:  Drug Healthc Patient Saf       Date:  2012-03-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.